

(Neo-)Adjuvant Chemotherapy in Early Stage Breast Cancer

| | Node -ve | | Node +ve or high risk node -ve | | Triple Negative Consider: |
|---|--|---|---|--|--|
| | Her2 -ve | Her2 +ve | Her2 -ve | Her2 +ve | |
| Neo-adjuvant | AC (dose dense) - Weekly Paclitaxel × 12 weeks OR EC ₁₀₀ -T* | Docetaxel* + Carboplatin + Trastuzumab + Pertuzumab** (TCHP) OR EC ₁₀₀ -T* HP** | AC (dose dense)- Weekly Paclitaxel × 12 weeks OR EC ₁₀₀ -T* | Docetaxel* + Carboplatin + Trastuzumab + Pertuzumab (TCHP) OR EC ₁₀₀ -T* HP | 3 Weekly Carboplatin + Weekly Paclitaxel × 12 weeks followed by: AC(dose dense) × 4 cycles OR EC ₁₀₀ × 3 cycles |
| Adjuvant | EC ₁₀₀ -T* OR TC × 4 cycles | EC ₁₀₀ -T* H OR Weekly Paclitaxel × 12 weeks + Trastuzumab OR Docetaxel + Carboplatin + Trastuzumab (TCH) | AC (dose dense) - Weekly Paclitaxel × 12 weeks OR FEC ₁₀₀ -T* | EC ₁₀₀ -T* PH OR Docetaxel + Carboplatin + Trastuzumab + Pertuzumab (TCHP) | AC (dose dense) - Weekly Paclitaxel × 12 weeks OR EC ₁₀₀ -T* |
| Contraindication to anthracycline or patient unsuitable for sequential anthracycline-taxane chemotherapy (neo-adjuvant or adjuvant) | Docetaxel + Cyclophosphamide × 4 cycles | Docetaxel + Carboplatin + Trastuzumab (TCH) (if neo-adjuvant add Pertuzumab**) OR Weekly Paclitaxel × 12 weeks + Trastuzumab | Docetaxel + Cyclophosphamide × 4 cycles | Docetaxel* + Carboplatin + Trastuzumab + Pertuzumab (TCHP) OR Weekly Paclitaxel × 12 weeks + Trastuzumab | Docetaxel + Cyclophosphamide × 4 cycles |
| <u>Plus for:</u> Postmenopausal women or Premenopausal women with a medical menopause. AND Patients with sufficient risk of relapse to benefit from this adjuvant treatment (consider in all node positive, ER negative and /or HER2 positive as well as high risk ER positive) | Adjuvant Zoledronic acid 6 monthly x 3 years | | | | |

* Docetaxel may be substituted with Weekly Paclitaxel to cover the same treatment period. ** Pertuzumab only if tumour is ≥2cm if node negative disease.

Treatments Highlighted in Red text require Blueteq Authorisation

| | | | |
|-------------------------|---|---------------------------|--|
| Version No: 3.0 | Changes from previous Version: Addition of adjuvant Pertuzumab | | |
| Prepared By: Hani Hanna | Approved by Consultant Oncologist: Dr Martin Hogg | Date Approved: 12/07/2019 | |